This is a global, prospective, observational pregnancy exposure registry designed to evaluate pregnancy and infant outcomes following exposure to diroximel fumarate (Vumerity) in individuals with multiple sclerosis (MS). The registry aims to characterise the risk of major congenital malformations (MCMs) and other adverse pregnancy outcomes associated with DRF exposure during pregnancy.

• Diagnosed with MS.
• Currently pregnant.
• Either
  • Exposed to Vumerity at any time from two weeks after the first day of last menstrual period (LMP)

Or

• • No exposure to a disease modifying therapy (DMT) during the pregnancy.

• Diagnosis other than MS.
• Pregnancies of partners of male patients exposed to Vumerity.

Currently recruiting

Jill Summerhayes,
E: jill.summerhayes@austin.org.au    P: +61 3 9496 3705

• Full details of the trial can be found on the ANZCTR clinical trial database https://clinicaltrials.gov/study/NCT05658497

NSW/ACT/SA/VIC/QLD/WA/TAS

Yes

20/04/2026